Search

everythinglearnresearchcommunity

for

Search:↓

Late puberty may slightly lower prostate cancer risk, baldness is not linked to overall risk but less so with aggressive types, ibuprofen use may increase risk, and vitamins show no effect on risk.

Finasteride is safe for long-term use in prostate cancer treatment.

5α-reductase inhibitors can reduce prostate cancer risk but may increase high-grade tumors, needing more research.

Further research is needed to develop effective cancer prevention strategies.

Androgen deprivation therapy for prostate cancer can cause sexual, physical, and psychological side effects, and doctors should manage these carefully.

Finasteride, selenium, and vitamin E may help prevent prostate cancer.

Five-alpha reductase inhibitors, like finasteride and dutasteride, can treat enlarged prostates, improve urination, reduce need for prostate surgery, and lower the risk of prostate cancer, but may increase the risk of higher grade prostate cancer. They can also treat male pattern baldness.

5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.

Chemoprevention can significantly lower cancer risks and needs more research and collaboration.

5-Alpha reductase inhibitors are safe long-term but may be outdated for preventing less significant prostate cancer.

Taking 1 mg/day finasteride for hair loss significantly lowers PSA levels in men, which may affect prostate cancer screening.

Finasteride 1 mg may help prevent prostate issues, but more research is needed to confirm its benefits.

A new drug, dutasteride, is at least as effective as the older drug, finasteride, for treating enlarged prostate and may have additional uses.

Finasteride reduces prostate cancer risk by 30% without affecting Gleason scores.

Dutasteride works better than finasteride for preventing and treating prostate cancer.

Sorafenib helps some advanced cancers alone or with other treatments, but not all, and research continues to improve its use.

Some patients taking finasteride or dutasteride may have ongoing sexual problems and depression even after stopping the medication.

The document concludes that better research methods are needed in men's sexual health to provide stronger evidence and improve patient care.

Preventing cancer involves lifestyle changes, vaccinations, early screening, and understanding cancer's molecular basis.

2007 research improved understanding of prostate cancer risk, diagnosis, and treatment, but also showed the need for personalized treatment and further study on certain therapies' risks.

In 2007, prostate cancer research improved understanding of risk, diagnosis, and treatment, but also showed heart risks with certain therapies and the need for personalized care.

Men who start losing hair at 20 may have a higher chance of getting prostate cancer later.

Men, especially older ones with health issues like prostate cancer, may have worse COVID-19 outcomes and could benefit from therapies targeting male hormones.

Men who experienced baldness at age 20 may have double the risk of getting prostate cancer.

Finasteride for hair loss lowers PSA levels, so PSA values need adjusting when screening for prostate cancer.

5α-reductase inhibitors like Finasteride and Dutasteride may help manage prostate cancer by blocking testosterone conversion.

The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.

Certain natural compounds called terpenes may help prevent prostate cancer.

Some natural compounds may help overcome drug resistance in certain cancers, but more research is needed.

Finasteride treats hair loss and reduces prostate cancer risk.